Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 13 studies | 25% ± 7% | |
B cell | 7 studies | 20% ± 3% | |
ciliated cell | 7 studies | 24% ± 9% | |
astrocyte | 6 studies | 25% ± 5% | |
oligodendrocyte | 6 studies | 33% ± 9% | |
macrophage | 6 studies | 23% ± 3% | |
GABAergic neuron | 5 studies | 31% ± 12% | |
epithelial cell | 5 studies | 32% ± 9% | |
type I pneumocyte | 5 studies | 22% ± 4% | |
microglial cell | 5 studies | 25% ± 6% | |
myeloid cell | 4 studies | 24% ± 4% | |
retinal rod cell | 4 studies | 22% ± 6% | |
glutamatergic neuron | 4 studies | 44% ± 14% | |
oligodendrocyte precursor cell | 4 studies | 36% ± 7% | |
dendritic cell | 4 studies | 24% ± 6% | |
basal cell | 4 studies | 23% ± 10% | |
pericyte | 4 studies | 22% ± 3% | |
myofibroblast cell | 3 studies | 19% ± 5% | |
fibroblast | 3 studies | 20% ± 2% | |
adipocyte | 3 studies | 19% ± 2% | |
type II pneumocyte | 3 studies | 19% ± 2% | |
alveolar macrophage | 3 studies | 22% ± 3% | |
monocyte | 3 studies | 27% ± 11% | |
smooth muscle cell | 3 studies | 17% ± 1% | |
interneuron | 3 studies | 34% ± 17% | |
neuron | 3 studies | 34% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2223.21 | 245 / 245 | 100% | 15.19 | 502 / 502 |
thymus | 100% | 1865.38 | 653 / 653 | 100% | 13.50 | 605 / 605 |
lung | 100% | 2076.00 | 578 / 578 | 100% | 10.48 | 1154 / 1155 |
breast | 100% | 1758.78 | 459 / 459 | 100% | 13.32 | 1117 / 1118 |
ovary | 100% | 1601.33 | 180 / 180 | 100% | 7.85 | 429 / 430 |
stomach | 100% | 1293.67 | 359 / 359 | 100% | 11.31 | 285 / 286 |
brain | 100% | 1304.48 | 2632 / 2642 | 100% | 13.17 | 704 / 705 |
esophagus | 100% | 2355.48 | 1445 / 1445 | 99% | 11.97 | 182 / 183 |
intestine | 100% | 1883.13 | 966 / 966 | 99% | 10.90 | 524 / 527 |
skin | 100% | 2312.91 | 1809 / 1809 | 99% | 11.08 | 469 / 472 |
bladder | 100% | 1589.10 | 21 / 21 | 99% | 11.29 | 498 / 504 |
kidney | 100% | 1452.16 | 89 / 89 | 99% | 12.34 | 890 / 901 |
pancreas | 98% | 886.25 | 323 / 328 | 100% | 10.39 | 178 / 178 |
uterus | 100% | 1751.82 | 170 / 170 | 98% | 9.25 | 450 / 459 |
adrenal gland | 100% | 1448.89 | 258 / 258 | 95% | 7.96 | 218 / 230 |
liver | 100% | 745.38 | 225 / 226 | 85% | 3.74 | 344 / 406 |
adipose | 100% | 1592.11 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1634.73 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 11.26 | 29 / 29 |
muscle | 100% | 1308.39 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2136.29 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 7.79 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.46 | 1 / 1 |
heart | 98% | 998.03 | 847 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 7.78 | 78 / 80 |
peripheral blood | 91% | 927.42 | 850 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0045087 | Biological process | innate immune response |
GO_0051865 | Biological process | protein autoubiquitination |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0016239 | Biological process | positive regulation of macroautophagy |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0009653 | Biological process | anatomical structure morphogenesis |
GO_0044790 | Biological process | suppression of viral release by host |
GO_0036503 | Biological process | ERAD pathway |
GO_0032897 | Biological process | negative regulation of viral transcription |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0097038 | Cellular component | perinuclear endoplasmic reticulum |
GO_0005737 | Cellular component | cytoplasm |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0061659 | Molecular function | ubiquitin-like protein ligase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TRIM13 |
Protein name | Tripartite motif containing 13 E3 ubiquitin-protein ligase TRIM13 (EC 2.3.2.27) (B-cell chronic lymphocytic leukemia tumor suppressor Leu5) (Leukemia-associated protein 5) (Putative tumor suppressor RFP2) (RING finger protein 77) (RING-type E3 ubiquitin transferase TRIM13) (Ret finger protein 2) (Tripartite motif-containing protein 13) Alternative protein TRIM13 |
Synonyms | RNF77 LEU5 RFP2 |
Description | FUNCTION: Endoplasmic reticulum (ER) membrane anchored E3 ligase involved in the retrotranslocation and turnover of membrane and secretory proteins from the ER through a set of processes named ER-associated degradation (ERAD). This process acts on misfolded proteins as well as in the regulated degradation of correctly folded proteins. Enhances ionizing radiation-induced p53/TP53 stability and apoptosis via ubiquitinating MDM2 and AKT1 and decreasing AKT1 kinase activity through MDM2 and AKT1 proteasomal degradation. Regulates ER stress-induced autophagy, and may act as a tumor suppressor . Also plays a role in innate immune response by stimulating NF-kappa-B activity in the TLR2 signaling pathway. Ubiquitinates TRAF6 via the 'Lys-29'-linked polyubiquitination chain resulting in NF-kappa-B activation . Participates as well in T-cell receptor-mediated NF-kappa-B activation . In the presence of TNF, modulates the IKK complex by regulating IKBKG/NEMO ubiquitination leading to the repression of NF-kappa-B . . |
Accessions | O60858 ENST00000442421.5 ENST00000356017.8 [O60858-3] X6RH27 ENST00000378183.8 ENST00000378182.4 [O60858-1] L8E9D0 ENST00000457662.2 [O60858-1] ENST00000420995.6 [O60858-1] X6R9U5 |